Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Fludarabine phosphate
Drug ID BADD_D00915
Description Not Available
Indications and Usage Not Available
Marketing Status Not Available
ATC Code Not Available
DrugBank ID Not Available
KEGG ID D01907
MeSH ID C042382
PubChem ID 30751
TTD Drug ID D0TO2R
NDC Product Code 58623-0043; 45963-609; 25021-242; 59923-604; 0527-1242; 51916-310; 33656-0015; 24201-237; 63323-192; 53183-7841
UNII 1X9VK9O1SC
Synonyms fludarabine phosphate | fludarabine 5'-monophosphate | 9 beta-D-arabinofuranosyl-2-fluoroadenine monophosphate | fludarabine monophosphate | FaraAMP | fluoro-ara-AMP | 9H-purin-6-amine, 2-fluoro-9-(5-O-phosphono-beta-D-arabinofuranosyl)- | F-ara-AMP | NSC 312887 | NSC-312887 | Beneflur | Fludara
Chemical Information
Molecular Formula C10H13FN5O7P
CAS Registry Number 75607-67-9
SMILES C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)COP(=O)(O)O)O)O)F)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Transient ischaemic attack24.04.06.005; 17.08.04.001--
Tumour lysis syndrome16.32.03.002; 14.05.01.004--
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urinary hesitation20.02.02.009--Not Available
Urinary tract infection11.01.14.004; 20.08.02.001--
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Mental status changes19.07.01.001--Not Available
Hypoacusis04.02.01.006--
Precancerous skin lesion23.01.06.004--Not Available
Deep vein thrombosis24.01.02.003--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Protein urine present13.13.02.006--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Acquired haemophilia01.01.01.002--Not Available
Evans syndrome10.04.01.003; 01.06.01.002--Not Available
Haemorrhage24.07.01.002--Not Available
Skin toxicity23.03.03.032; 12.03.01.020--Not Available
Lymphoproliferative disorder16.21.02.001; 01.13.02.001--Not Available
Malnutrition14.03.02.004--Not Available
Optic nerve disorder17.04.05.004; 06.02.08.001--
Optic neuropathy17.04.05.005; 06.02.08.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Renal function test abnormal13.13.01.012--Not Available
Ill-defined disorder08.01.03.049--Not Available
Immunodeficiency10.03.02.002--Not Available
Pulmonary toxicity22.01.02.007; 12.03.01.013--Not Available
Bone marrow failure01.03.03.005--
Cytopenia01.03.03.012--Not Available
X-linked lymphoproliferative syndrome16.21.02.003; 11.05.10.005; 10.03.01.003; 03.17.01.002; 01.13.02.003--Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages